tACS for Phonological Memory After Stroke — Rehabilitation, Not Enhancement

What is being studied

A randomised, triple-masked trial at the Medical College of Wisconsin is testing high-definition transcranial alternating current stimulation against sham stimulation for the recovery of phonological short-term memory in people with aphasia after stroke. It is recruiting, with 120 participants planned, and runs to 2033.

Two primary outcomes are registered: accuracy on a phonological short-term memory task, and functional MRI measures of language network activation. Both are assessed after a therapy cycle of ten intervention days and again ten weeks later.

This is rehabilitation, not enhancement

The distinction matters more than anything else in this note. tACS reaches consumer discussion as a way of improving memory in healthy people. This trial is about recovering a specific language function in people who lost it to a stroke.

Those are different questions with different plausibility. A damaged network being helped toward reorganisation is a far more modest proposition than a healthy network being pushed above its normal performance, and evidence for one says little about the other.

The inclusion of an fMRI endpoint alongside the behavioural one is a strength. A behavioural improvement with no corresponding change in language network activation would be a different and weaker finding than the two moving together.

The state of the wider evidence

A systematic review and meta-analysis in Science Translational Medicine pooled 102 published studies covering 2,893 individuals in healthy, ageing and neuropsychiatric populations, extracting 304 separate effects, and reported that tACS improves cognition across those groups.

That is a substantial body of work and it is why this technique is taken seriously. A separate systematic review in Cortex, examining tACS specifically against sham stimulation for working and long-term memory, framed the question as one of how effective the technique actually is — the more cautious framing of the two.

The tension between them is characteristic of a field with many small studies and heterogeneous protocols. Frequency, electrode montage, current intensity, timing relative to the task and the individual's own oscillatory frequency all vary between experiments, and pooling across them assumes a comparability that has not been established.

Why the timeline is worth noting

Estimated completion is 2033. That is a long horizon, and it reflects the difficulty of recruiting people with a specific post-stroke profile into a demanding multi-visit protocol.

It is also a useful corrective to the pace at which brain stimulation is discussed commercially. Devices are marketed on the strength of literature that trials like this one exist to test properly, and the testing takes a decade.

Editorial Comment

MindHeaven® does not sell or endorse brain stimulation devices, and nothing in this note should be read as suggesting that consumer tACS equipment does what a supervised clinical protocol does.

Stroke and aphasia are medical conditions requiring specialist care. We record this trial because the technique it tests is being sold to consumers well ahead of the evidence, and knowing what a proper trial of it looks like — sham-controlled, triple-masked, with an imaging endpoint and a ten-year timeline — is a reasonable defence against that.